These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24939980)

  • 1. Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort.
    Karim ME; Gustafson P; Petkau J; Zhao Y; Shirani A; Kingwell E; Evans C; van der Kop M; Oger J; Tremlett H
    Am J Epidemiol; 2014 Jul; 180(2):160-71. PubMed ID: 24939980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
    Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
    JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dealing With Treatment-Confounder Feedback and Sparse Follow-up in Longitudinal Studies: Application of a Marginal Structural Model in a Multiple Sclerosis Cohort.
    Karim ME; Tremlett H; Zhu F; Petkau J; Kingwell E
    Am J Epidemiol; 2021 May; 190(5):908-917. PubMed ID: 33125039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New natural history of interferon-beta-treated relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Fuiani A; Paolicelli D; Zipoli V; Zimatore GB; Di Monte E; Portaccio E; Lepore V; Livrea P; Amato MP
    Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-beta and disability progression in relapsing-remitting multiple sclerosis.
    Drulovic J; Kostic J; Mesaros S; Dujmovic Basuroski I; Stojsavljevic N; Kisic-Tepavcevic D; Pekmezovic T
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S65-9. PubMed ID: 24321159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating inverse probability weights using super learner when weight-model specification is unknown in a marginal structural Cox model context.
    Karim ME; Platt RW;
    Stat Med; 2017 Jun; 36(13):2032-2047. PubMed ID: 28219110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
    Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study.
    Shirani A; Zhao Y; Karim ME; Petkau J; Gustafson P; Evans C; Kingwell E; van der Kop ML; Oger J; Tremlett H
    Eur J Neurol; 2014 Jun; 21(6):835-44. PubMed ID: 24351059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scoring treatment response in patients with relapsing multiple sclerosis.
    Sormani MP; Rio J; Tintorè M; Signori A; Li D; Cornelisse P; Stubinski B; Stromillo Ml; Montalban X; De Stefano N
    Mult Scler; 2013 Apr; 19(5):605-12. PubMed ID: 23012253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
    Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
    Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C; Oger J; Gibbs E; Grossberg SE;
    Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis: effect of beta interferon treatment on survival.
    Kingwell E; Leray E; Zhu F; Petkau J; Edan G; Oger J; Tremlett H
    Brain; 2019 May; 142(5):1324-1333. PubMed ID: 30883636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of statistical approaches dealing with time-dependent confounding in drug effectiveness studies.
    Karim ME; Petkau J; Gustafson P; Platt RW; Tremlett H;
    Stat Methods Med Res; 2018 Jun; 27(6):1709-1722. PubMed ID: 27659168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.
    Kieseier BC
    Expert Rev Neurother; 2014 Jan; 14(1):105-20. PubMed ID: 24417500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.
    Kalincik T; Jokubaitis V; Izquierdo G; Duquette P; Girard M; Grammond P; Lugaresi A; Oreja-Guevara C; Bergamaschi R; Hupperts R; Grand'Maison F; Pucci E; Van Pesch V; Boz C; Iuliano G; Fernandez-Bolanos R; Flechter S; Spitaleri D; Cristiano E; Verheul F; Lechner-Scott J; Amato MP; Cabrera-Gomez JA; Saladino ML; Slee M; Moore F; Gray O; Paine M; Barnett M; Havrdova E; Horakova D; Spelman T; Trojano M; Butzkueven H;
    Mult Scler; 2015 Aug; 21(9):1159-71. PubMed ID: 25480857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
    Hutchinson M; Kappos L; Calabresi PA; Confavreux C; Giovannoni G; Galetta SL; Havrdova E; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    J Neurol; 2009 Mar; 256(3):405-15. PubMed ID: 19308305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis.
    Newsome SD; Guo S; Altincatal A; Proskorovsky I; Kinter E; Phillips G; You X; Sabatella G
    Mult Scler Relat Disord; 2015 Jul; 4(4):350-7. PubMed ID: 26195056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.